The Centers for Medicare and Medicaid Services is drawing fire for refusing to cover immunotherapy drugs that target early-stage Alzheimer’s disease, although the U.S. Food and Drug Administration has approved them.
The Centers for Medicare and Medicaid Services is drawing fire for refusing to cover immunotherapy drugs that target early-stage Alzheimer’s disease, although the U.S. Food and Drug Administration has approved them.